Leerink Partners Has Lowered Expectations for Insulet (NASDAQ:PODD) Stock Price

Insulet (NASDAQ:PODD) had its target price reduced by equities research analysts at Leerink Partners from $360.00 to $247.00 in a note issued to investors on Thursday,MarketScreener reports. Leerink Partners’ price objective would indicate a potential upside of 60.22% from the stock’s current price.

Other analysts also recently issued research reports about the stock. Truist Financial decreased their price target on shares of Insulet from $360.00 to $315.00 and set a “buy” rating for the company in a research report on Wednesday, April 15th. BTIG Research decreased their price target on shares of Insulet from $320.00 to $260.00 and set a “buy” rating for the company in a research report on Wednesday. TD Cowen downgraded shares of Insulet from a “buy” rating to a “hold” rating and set a $294.00 price target for the company. in a research report on Monday, January 26th. Stifel Nicolaus decreased their price objective on shares of Insulet from $370.00 to $350.00 and set a “buy” rating for the company in a report on Wednesday, February 4th. Finally, Sanford C. Bernstein decreased their price objective on shares of Insulet from $330.00 to $200.00 and set an “outperform” rating for the company in a report on Thursday. Eighteen equities research analysts have rated the stock with a Buy rating, five have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $257.09.

Insulet Stock Down 3.9%

PODD stock opened at $154.16 on Thursday. Insulet has a twelve month low of $148.30 and a twelve month high of $354.88. The company has a current ratio of 2.49, a quick ratio of 2.15 and a debt-to-equity ratio of 0.71. The company has a market capitalization of $10.68 billion, a P/E ratio of 35.85, a PEG ratio of 0.92 and a beta of 1.20. The firm has a 50 day simple moving average of $211.22 and a 200-day simple moving average of $263.85.

Insulet (NASDAQ:PODD) last released its quarterly earnings results on Wednesday, May 6th. The medical instruments supplier reported $1.42 earnings per share for the quarter, topping analysts’ consensus estimates of $1.19 by $0.23. Insulet had a net margin of 10.44% and a return on equity of 26.87%. The business had revenue of $761.70 million during the quarter, compared to the consensus estimate of $729.89 million. During the same quarter last year, the company earned $1.02 earnings per share. The business’s quarterly revenue was up 33.9% compared to the same quarter last year. Insulet has set its FY 2026 guidance at 6.210- EPS. On average, equities research analysts predict that Insulet will post 6.46 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Insulet news, Director Michael R. Minogue acquired 2,030 shares of the firm’s stock in a transaction on Wednesday, February 25th. The stock was purchased at an average price of $246.23 per share, with a total value of $499,846.90. Following the completion of the acquisition, the director directly owned 17,483 shares in the company, valued at $4,304,839.09. This trade represents a 13.14% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is accessible through the SEC website. 0.36% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Insulet

Several hedge funds and other institutional investors have recently modified their holdings of PODD. Larson Financial Group LLC boosted its holdings in shares of Insulet by 114.6% during the fourth quarter. Larson Financial Group LLC now owns 88 shares of the medical instruments supplier’s stock valued at $25,000 after acquiring an additional 47 shares during the period. University of Texas Texas AM Investment Management Co. acquired a new position in shares of Insulet during the fourth quarter valued at $26,000. Elyxium Wealth LLC acquired a new position in shares of Insulet during the fourth quarter valued at $28,000. DV Equities LLC acquired a new position in shares of Insulet during the fourth quarter valued at $28,000. Finally, MV Capital Management Inc. acquired a new position in shares of Insulet during the fourth quarter valued at $29,000.

Key Headlines Impacting Insulet

Here are the key news stories impacting Insulet this week:

• Positive Sentiment: Insulet’s Q1 results beat expectations, with revenue of $761.7 million and EPS of $1.42, and management raised full-year revenue growth guidance to 21%–23%, reinforcing momentum in its Omnipod diabetes platform.
• Positive Sentiment: The company highlighted strong international Omnipod growth and continued expansion of Omnipod 5 into new markets, which suggests the core business remains healthy. Article Title
• Neutral Sentiment: Recent earnings-call coverage and transcript coverage continued to emphasize improved profitability and upbeat management commentary following the Q1 report. Article Title
• Negative Sentiment: Multiple Wall Street firms cut price targets sharply after the earnings report, including Piper Sandler, JPMorgan, Citigroup, Wells Fargo, Stifel, Raymond James, Canaccord Genuity, Leerink, and others, which likely pressured the shares.
• Negative Sentiment: The stock is also trading well below several recent analyst targets, and the cluster of downgrades/target reductions may be signaling concerns about valuation or the pace of future upside despite the earnings beat.

About Insulet

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.